Author: Mary Boyajian

Ossium Health, a commercial-stage bioengineering company with the first-of-its-kind bone marrow bank for processing and deploying stem cell-based therapies, today announced the signing of a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to advance the company’s ready-to-use bone marrow for national emergency preparedness. The contract, initially funded at $21 million for its base period, has the potential to reach a total value of $125 million with additional options spanning five years.

Read the full press release here.

Ossium Health, a clinical-stage bioengineering company that built a first-of-its-kind organ donor-derived bone marrow bank to deploy hematopoietic stem cells for blood cancer treatment, announced positive preliminary outcomes for its first leukemia patient.

In Detroit, a 68-year-old female diagnosed with acute myeloid leukemia required an urgent bone marrow transplant following an unsuccessful four-month search for a matching donor. Doctors at Henry Ford Health collaborated with Ossium in June to obtain and use Ossium’s stem cell product to treat the patient. Specifically, the patient received an infusion of 5.27 million CD34+ cells per kilogram of body weight from a donor that was a 4/8 HLA match to the patient. The doctors reported neutrophil engraftment by day 16 post-transplant and platelet engraftment by day 21. There have been no reported product-related adverse events to date.

Read the full press release here.